欧洲下一代测序 (NGS) 市场，按产品（仪器、消耗品和服务）、应用（诊断、生物标志物发现、精准医疗、药物发现、农业和动物研究等）、最终用户（制药和生物技术公司、研究中心和学术和政府机构以及医院和诊所）、国家（德国、英国、意大利、法国、西班牙、瑞士、俄罗斯、土耳其、比利时、荷兰和欧洲其他地区）行业趋势和预测到 2029 年。
市场分析和见解：欧洲下一代测序 (NGS) 市场
欧洲下一代测序 (NGS) 市场预计将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2022 年至 2029 年的预测期内，该市场以 15.7% 的复合年增长率增长，预计到 2029 年将达到 87.3308 亿美元。下一代测序研究活动的增加成为下一代测序 (NGS) 市场增长的驱动力。
高通量测序，被广泛认为是“下一代”测序 (NGS)，由于众多技术和功能的发展，现已融入常规临床实践，而早期的方案依赖于在临床病理学典型工作流程之外采集的样本，标准福尔马林固定、石蜡包埋样本，可更经常地用作 NGS 的起始材料。此外，正在积累用于分析和解释 NGS 数据的方案以及知识库，使临床医生能够在患者护理点更轻松地根据基因组信息采取行动。用于诊断慢性疾病的下一代测序产品种类繁多，满足了医疗机构的需求。技术进步的加快导致市场上开发出高效的下一代测序 (NGS)。
推动下一代测序（NGS）市场增长的主要因素是下一代测序在药物开发中的应用以及主要参与者提供的广泛产品组合，而阻碍下一代测序（NGS）市场增长的因素包括下一代测序产品的高成本和产品召回。
下一代测序 (NGS) 市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入领域、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和下一代测序 (NGS) 市场情景，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您创建收入影响解决方案以实现您的预期目标。
下一代测序 (NGS) 市场范围和市场规模
下一代测序 (NGS) 市场根据产品、应用和最终用户进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
- 根据产品，欧洲下一代测序 (NGS) 市场分为仪器、耗材和服务。2022 年，仪器部分预计将主导欧洲下一代测序 (NGS) 市场，因为欧洲国家拥有广泛的仪器组合，这也是贡献收入的主要部分。
- 根据应用，欧洲下一代测序 (NGS) 市场细分为诊断、药物发现、生物标志物发现、精准医疗、农业和动物研究。2022 年，诊断领域预计将主导欧洲下一代测序 (NGS) 市场，因为临床实验室和实验室正在使用 NGS 进行各种疾病的常规诊断，因为它有可能提供精确的测试结果并提供出色的治疗方案。
- 根据最终用户，欧洲下一代测序 (NGS) 市场细分为医院和诊所、研究中心和学术及政府机构、制药和生物技术公司。2022 年，研究中心和学术及政府机构预计将主导欧洲下一代测序 (NGS) 市场，因为众所周知，欧洲国家拥有先进的研究机构，这些机构不断与制药公司合作开发 NGS，
下一代测序 (NGS) 市场国家级分析
对下一代测序 (NGS) 市场进行了分析，并按上述国家、产品、应用和最终用户提供了市场规模信息。
下一代测序 (NGS) 市场报告涵盖的国家包括英国、德国、法国、西班牙、意大利、荷兰、瑞士、俄罗斯、土耳其、奥地利、爱尔兰和欧洲其他地区。
预计欧洲地区德国的研究中心和学术及政府机构部门将在 2022 年至 2029 年的预测期内以最高的增长率增长，因为这些进行基层研究的中心对 NGS 的使用不断增加。
报告的国家部分还提供了影响单个市场因素和国内市场法规变化，这些变化影响了市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了欧洲品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。
主要市场参与者不断增加的战略活动，以提高对下一代测序 (NGS) 治疗的认识，正在推动下一代测序 (NGS) 市场的增长
下一代测序 (NGS) 市场还为您提供每个国家特定市场增长的详细市场分析。此外，它还提供有关市场参与者战略及其地理分布的详细信息。数据适用于 2011 年至 2020 年的历史时期。
竞争格局和下一代测序 (NGS) 市场份额分析
下一代测序 (NGS) 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用主导地位、技术生命线曲线。以上提供的数据点仅与公司关注的下一代测序 (NGS) 市场有关。
从事下一代测序 (NGS) 的一些主要公司包括 Agilent Technologies, Inc.、ThermoFisher Scientific, Inc.、QIAGEN、Illumina, Inc.、Bio-Rad Laboratories, Inc.、BGI（BGI 集团的子公司）、Oxford Nanopore Technologies plc 以及其他国内公司。DBMR 分析师了解竞争优势并为每个竞争对手分别提供竞争分析。
全球各地的公司也签订了许多合同和协议，这也正在加速下一代测序（NGS）市场的发展。
例如，
- 2021 年 2 月，赛默飞世尔科技公司宣布其在年度 CMO 领导力奖中获得六个奖项。该奖项由 Life Science Leader 和 Outsourced Pharma 颁发，旨在表彰生物制药和生物技术公司评选出的顶级合同制造合作伙伴。据估计，这一认可有望加强公司在欧洲市场的影响力，并在未来几年推动公司的增长。
市场参与者的合作、产品发布、业务扩展、奖励和认可、合资企业和其他策略正在增强公司在下一代测序 (NGS) 市场的影响力，这也为组织的利润增长带来了好处。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 PESTEL'S ANALYSIS
3.2 PORTER'S FIVE FORCES MODEL
4 REGULATIONS OF EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 DECREASE IN THE COST OF GENETIC SEQUENCING PER BASE
5.1.2 INCREASE IN THE ADOPTION OF GENOME-FOCUSED PHARMACOLOGY
5.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY MAJOR PLAYER
5.1.4 USE OF NEXT GENERATION SEQUENCING IN DRUG DEVELOPMENT
5.1.5 INCREASED TREND TOWARDS PERSONALIZED MEDICATION
5.2 RESTRAINTS
5.2.1 HIGH COST OF INSTRUMENT
5.2.2 DIFFICULTY IN CLINICAL NGS DATA ANALYSIS
5.2.3 CYBER SECURITY CONCERN IN GENOMICS
5.3 OPPORTUNITIES
5.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER
5.3.2 PRODUCT APPROVAL IN RECENT YEARS
5.3.3 ADVANCEMENT IN NGS TECHNOLOGY
5.4 CHALLENGES
5.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM NGS
5.4.2 CHALLENGES FOR IMPLEMENTING NGS IN THE CLINICAL LAB
6 IMPACT OF COVID-19 ON EUROPE NEXT GENERATION SEQUENCING (NGS) HEALTHCARE INDUSTRY
6.1 IMPACT ON PRICE
6.2 IMPACT ON DEMAND
6.3 IMPACT ON SUPPLY CHAIN
6.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
6.5 CONCLUSION
7 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 INSTRUMENTS
7.2.1 HISEQ SERIES
7.2.2 MISEQ SERIES
7.2.3 ION TORRENT
7.2.4 PACBIO RS II
7.2.5 SEQUEL SYSTEM
7.2.6 SOLID
7.2.7 OTHERS
7.3 CONSUMABLE
7.3.1 LIBRARY PREPARATION & TARGET ENRICHMENT
7.3.2 SAMPLE PREPARATION CONSUMABLES
7.3.3 OTHERS
7.4 SERVICES
7.4.1 SEQUENCING SERVICES
7.4.2 DATA MANAGEMENT
8 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 DIAGNOSTICS
8.3 BIOMARKER DISCOVERY
8.4 PRECISION MEDICINE
8.5 DRUG DISCOVERY
8.6 AGRICULTURE & ANIMAL RESEARCH
9 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER
9.1 OVERVIEW
9.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
9.3 RESEARCH CENTERS & ACADEMIC AND GOVERNMENT INSTITUTES
9.4 HOSPITAL & CLINICS
10 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION
10.1 EUROPE
10.1.1 GERMANY
10.1.2 FRANCE
10.1.3 U.K.
10.1.4 ITALY
10.1.5 RUSSIA
10.1.6 SPAIN
10.1.7 SWITZERLAND
10.1.8 NETHERLANDS
10.1.9 BELGIUM
10.1.10 TURKEY
10.1.11 REST OF EUROPE
11 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: EUROPE
12 COMPANY PROFILING
12.1 ILLUMINA, INC.
12.1.1 COMPANY SNAPSHOT
12.1.2 REVENUE ANALYSIS
12.1.3 COMPANY SHARE ANALYSIS
12.1.4 SWOT ANALYSIS
12.1.5 PRODUCT PORTFOLIO
12.1.6 RECENT DEVELOPMENTS
12.2 BGI (A SUBSIDIAIRY OF BGI GROUP) (2021)
12.2.1 COMPANY SNAPSHOT
12.2.2 REVENUE ANALYSIS
12.2.3 COMPANY SHARE ANALYSIS
12.2.4 SWOT ANALYSIS
12.2.5 PRODUCT PORTFOLIO
12.2.6 RECENT DEVELOPMENT
12.3 THERMO FISHER SCIENTIFIC INC.
12.3.1 COMPANY SNAPSHOT
12.3.2 REVENUE ANALYSIS
12.3.3 COMPANY SHARE ANALYSIS
12.3.4 SWOT ANALYSIS
12.3.5 PRODUCT PORTFOLIO
12.3.6 RECENT DEVELOPMENTS
12.4 QIAGEN
12.4.1 COMPANY SNAPSHOT
12.4.2 REVENUE ANALYSIS
12.4.3 COMPANY SHARE ANALYSIS
12.4.4 SWOT ANALYSIS
12.4.5 PRODUCT PORTFOLIO
12.4.6 RECENT DEVELOPMENTS
12.5 AGILENT TECHNOLOGIES, INC.
12.5.1 COMPANY SNAPSHOT
12.5.2 REVENUE ANALYSIS
12.5.3 COMPANY SHARE ANALYSIS
12.5.4 SWOT ANALYSIS
12.5.5 PRODUCT PORTFOLIO
12.5.6 RECENT DEVELOPMENT
12.6 OXFORD NANOPORE TECHNOLOGIES
12.6.1 COMPANY SNAPSHOT
12.6.2 PRODUCT PORTFOLIO
12.6.3 RECENT DEVELOPMENTS
12.7 BIO-RAD LABORATORIES, INC.
12.7.1 COMPANY SNAPSHOT
12.7.2 REVENUE ANALYSIS
12.7.3 PRODUCT PORTFOLIO
12.7.4 RECENT DEVELOPMENTS
12.8X GENOMICS
12.8.1 COMPANY SNAPSHOT
12.8.2 REVENUE ANALYSIS
12.8.3 PRODUCT PORTFOLIO
12.8.4 RECENT DEVELOPMENTS
12.9 BIOMÉRIEUX SA
12.9.1 COMPANY SNAPSHOT
12.9.2 REVENUE ANALYSIS
12.9.3 PRODUCT PORTFOLIO
12.9.4 RECENT DEVELOPMENT
12.1 DNASTAR
12.10.1 COMPANY SNAPSHOT
12.10.2 PRODUCT PORTFOLIO
12.10.3 RECENT DEVELOPMENT
12.11 GENEIOUS
12.11.1 COMPANY SNAPSHOT
12.11.2 PRODUCT PORTFOLIO
12.11.3 RECENT DEVELOPMENTS
12.12 GENEWIZ, FROM AZENTA LIFE SCIENCES
12.12.1 COMPANY SNAPSHOT
12.12.2 REVENUE ANALYSIS
12.12.3 PRODUCT PORTFOLIO
12.12.4 RECENT DEVELOPMENTS
12.13 HAMILTON COMPANY
12.13.1 COMPANY SNAPSHOT
12.13.2 PRODUCT PORTFOLIO
12.13.3 RECENT DEVELOPMENT
12.14 MACROGEN, INC.
12.14.1 COMPANY SNAPSHOT
12.14.2 REVENUE ANALYSIS
12.14.3 PRODUCT PORTFOLIO
12.14.4 RECENT DEVELOPMENT
12.15 NEW ENGLAND BIOLABS
12.15.1 COMPANY SNAPSHOT
12.15.2 PRODUCT PORTFOLIO
12.15.3 RECENT DEVELOPMENT
12.16 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
12.16.1 COMPANY SNAPSHOT
12.16.2 REVENUE ANALYSIS
12.16.3 PRODUCT PORTFOLIO
12.16.4 RECENT DEVELOPMENTS
12.17 PARTEK, INCORPORATED
12.17.1 COMPANY SNAPSHOT
12.17.2 PRODUCT PORTFOLIO
12.17.3 RECENT DEVELOPMENT
12.18 PERKIN ELMER INC. (2021)
12.18.1 COMPANY SNAPSHOT
12.18.2 REVENUE ANALYSIS
12.18.3 PRODUCT PORTFOLIO
12.18.4 RECENT DEVELOPMENTS
12.19 ROCHE SEQUENCING (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)
12.19.1 COMPANY SNAPSHOT
12.19.2 REVENUE ANALYSIS (PARENT COMPANY)
12.19.3 PRODUCT PORTFOLIO
12.19.4 RECENT DEVELOPMENTS
12.2 TAKARA BIO INC.
12.20.1 COMPANY SNAPSHOT
12.20.2 REVENUE ANALYSIS
12.20.3 PRODUCT PORTFOLIO
12.20.4 RECENT DEVELOPMENTS
13 QUESTIONNAIRE
14 RELATED REPORTS
表格列表
TABLE 1 NEXT GENERATION SEQUENCING COST PER SAMPLE
TABLE 2 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 3 EUROPE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 5 EUROPE CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 7 EUROPE SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 9 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE DRUG DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE AGRICULTURE & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 16 EUROPE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE RESEARCH CENTERS & ACADEMIC AND GOVERNMENT INSTITUTES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE HOSPITAL & CLINICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 20 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 21 EUROPE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 22 EUROPE CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 23 EUROPE SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 24 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 25 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 26 GERMANY NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 27 GERMANY INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 28 GERMANY CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 29 GERMANY SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 30 GERMANY NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 31 GERMANY NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 32 FRANCE NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 33 FRANCE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 34 FRANCE CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 35 FRANCE SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 36 FRANCE NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 37 FRANCE NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 38 U.K. NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 39 U.K. INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 40 U.K. CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 41 U.K. SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 42 U.K. NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 43 U.K. NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 44 ITALY NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 45 ITALY INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 46 ITALY CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 47 ITALY SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 48 ITALY NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 49 ITALY NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 50 RUSSIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 51 RUSSIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 52 RUSSIA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 53 RUSSIA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 54 RUSSIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 55 RUSSIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 56 SPAIN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 57 SPAINSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 58 SPAIN CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 59 SPAIN SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 60 SPAIN NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 61 SPAIN NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 62 SWITZERLAND NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 63 SWITZERLAND INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 64 SWITZERLAND CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 65 SWITZERLAND SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 66 SWITZERLAND NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 67 SWITZERLAND NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 68 NETHERLANDS NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 69 NETHERLANDS INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 70 NETHERLANDS CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 71 NETHERLANDS SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 72 NETHERLANDS NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 73 NETHERLANDS NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 74 BELGIUM NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 75 BELGIUM INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 76 BELGIUM CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 77 BELGIUM SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 78 BELGIUM NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 79 BRLGIUM NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 80 TURKEY NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 81 TURKEY INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 82 TURKEY CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 83 TURKEY SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 84 TURKEY NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 85 TURKEY NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 86 REST OF EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: SEGMENTATION
FIGURE 2 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: DROC ANALYSIS
FIGURE 4 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: SEGMENTATION
FIGURE 11 WISE PORTFOLIO OFFERED BY MAJOR PLAYERS AND USE OF NEXT GENERATION SEQUENCING IN DRUG DEVELOPMENT IS EXPECTED TO DRIVE THE EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INSTRUMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET IN 2021 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET
FIGURE 14 DECREASE IN COST OF PER BASE SEQUENCING
FIGURE 15 USE OF NSG IN DRUG DEVELOPMENT
FIGURE 16 REVENUE OF THE COMPANY AGILENT TECHNOLOGIES, INC.
FIGURE 17 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, 2021
FIGURE 18 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, 2020-2029 (USD MILLION)
FIGURE 19 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 20 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 21 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, 2021
FIGURE 22 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, 2020-2029 (USD MILLION)
FIGURE 23 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 24 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 25 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, 2021
FIGURE 26 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 27 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, CAGR (2022-2029)
FIGURE 28 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, LIFELINE CURVE
FIGURE 29 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: SNAPSHOT (2021)
FIGURE 30 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2021)
FIGURE 31 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 32 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 33 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT (2022-2029)
FIGURE 34 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
